PAP
PALI icon

Persistent Asset Partners’s Palisade Bio PALI Stock Holding History

Persistent Asset Partners’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.7K Sell
41,464
-194,884
-82% -$384K 0.03% 316
2026
Q1 		$414K Sell
236,348
-179,687
-43% -$327K 0.15% 126
2025
Q4 		$978K Buy
+416,035
New +$800K 0.44% 63

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Persistent Asset Partners's PALI Position: Q2 2026 in Review

Persistent Asset Partners reduced its Palisade Bio (PALI) stake by 82% in Q2 2026, selling an estimated $384K and leaving 41,464 shares worth $86.7K. The position accounts for 0.03% of the portfolio, ranked #316.

Persistent Asset Partners first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. The position peaked at $978K in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Persistent Asset Partners held 41,464 shares of Palisade Bio worth $86.7K as of Q2 2026.
  • Persistent Asset Partners sold 194,884 Palisade Bio shares in Q2 2026, an estimated $384K.
  • Palisade Bio made up 0.03% of Persistent Asset Partners's portfolio in Q2 2026, its #316 holding.
  • Persistent Asset Partners first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Palisade Bio position peaked at $978K in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.